Novo Nordisk shares positive results from COMBINE 3 phase 3a trial

Betsy Goodfellow | January 10, 2024 | News story | Research and Development Diabetes, IcoSema, Novo Nordisk, clinical trial, diabetes 

Novo Nordisk has shared topline results from the COMBINE 3 phase 3a trial of once-weeklly IcoSema, a fixed-ration combination treatment consisting of basal insulin icodec and semaglutide.

The trial was a 52-week, open-label treat-to-target trial which assessed the efficacy and safety of once-weekly IcoSema compared to once-daily insulin glargine U100 and insulin aspart (injected 2-4 times each day during mealtimes), dosed with or without oral glucose-lowering medications. The trial included 679 people with type 2 diabetes inadequately controlled currently being treated with daily basal insulin.

The trial met its primary endpoint of demonstrating non-inferiority in reducing HbA1c at week 52 with once-weekly IcoSema compared with treatment with insulin glargine U100 and insulin aspart.

Martin Holst Lange, executive vice president for Development at Novo Nordisk, commented: “We are very pleased to share the first phase 3a results for once-weekly IcoSema. The results demonstrate the potential of IcoSema to simplify insulin intensification by reducing the injection burden to a single injection per week compared to around 28 injections per week for people with type 2 diabetes inadequately controlled on basal insulin while providing glycaemic control as well as weight benefits and lower rates of hypoglycaemia.”

Betsy Goodfellow

Related Content

AstraZeneca shares positive interim results from phase 3 lymphoma trial

AstraZeneca has announced positive high-level results from an interim analysis of the ECHO phase 3 …

Verona Pharma to share phase 3 COPD trial data at ATS 2024

Verona Pharma has announced that it will share eight posters at the American Thoracic Society …

Sanofi shares results for phase 3 LUNA 3 trial in immune thrombocytopenia

Sanofi has announced positive results from its phase 3 LUNA 3 study, which assessed rilzabrutinib …

Latest content